Eli Lilly shares jump more than 5% after Mounjaro and Zepbound boost quarterly sales mix, prompting an outlook change

Eli Lilly’s stock rose sharply after the company indicated stronger revenue expectations tied to demand for its blockbuster GLP-1 drugs. Shares jumped more than 5% in the market reaction described by Yahoo Finance, following a reassessment of the outlook after sales from Mounjaro and Zepbound climbed to a much larger share of the business.

At the center of the update were Mounjaro and Zepbound, Eli Lilly’s two major medicines in the company’s GLP-1 franchise. In the report, Yahoo Finance said Mounjaro and Zepbound together generated nearly two-thirds of Eli Lilly’s quarterly sales. The figure reflects not just growth in those products, but also a shift in the company’s overall sales composition toward weight-loss and related metabolic demand.

The surge was attributed to a steep increase in sales for the combined franchise, with the report characterizing growth at about 91% over the prior period. That kind of acceleration matters for Eli Lilly because it supports the company’s ability to sustain higher revenue even when other segments of the portfolio grow more slowly or face competitive pressures.

The report also said Eli Lilly raised its revenue outlook in response to the improved performance. Outlook revisions are closely watched in large-cap biopharma because they can indicate how management sees near-term supply, pricing, and demand trends playing out, and because they can alter analyst expectations for the full year and subsequent quarters.

Eli Lilly’s GLP-1 products have become a core driver for the sector more broadly, reshaping how investors value pharma companies with obesity and diabetes franchises. As those drugs contribute an increasing share of total sales, quarterly results tend to hinge on patient demand, reimbursement dynamics, and manufacturing capacity, rather than on progress across many smaller pipeline assets.

For the market, the immediate question after the update is whether the company can keep the growth pace while converting that sales momentum into sustained guidance. If Mounjaro and Zepbound remain dominant within the sales mix, Eli Lilly’s revenue outlook could remain sensitive to any changes in prescription growth, payer coverage, and prescription fill rates.

Still, the publicly reported information in the Yahoo Finance item does not spell out how much of the outlook change came from volume versus pricing, nor does it provide product-level breakdowns beyond the combined contribution and growth rate. It also does not detail any timing assumptions about future supply constraints or how quickly the company expects demand to normalize after rapid expansion.

What to watch next is follow-through on the raised revenue outlook and additional detail on the drivers behind it, including whether management addresses any risks to growth at future earnings and guidance updates. Investors will likely look for confirmation that Mounjaro and Zepbound continue to expand their share of quarterly sales, rather than reverting as the market digests earlier gains.